RNA250117C47000
- 0.16
- -0.89-84.76%
Avidity Biosciences Newsroom
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
H.C. Wainwright Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $72
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avidity Biosciences Price Target Announced at $72.00/Share by HC Wainwright & Co.
Avidity Biosciences Initiated at Buy by HC Wainwright & Co.
Express News | Avidity Biosciences Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $72
Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing
PepGen Stock Craters 35% on FDA Clinical Hold
Insider Sale: CSTO of $RNA (RNA) Sells 24,000 Shares
Avidity Biosciences (RNA) Receives a Buy From TD Cowen
Avidity Biosciences: Advancing Clinical Programs With Strategic Focus and Growth Potential
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Sale: Chief Human Resources Officer of $RNA (RNA) Sells 25,000 Shares
RNA Stock Hits Record High on Entering the Cardiac Disease Space